AC Immune FY2025 contract revenue fell 87% to CHF 3.57 million as net loss widened 38% to CHF 70.45 million

Reuters03-13

AC Immune FY2025 contract revenue fell 87% to CHF 3.57 million as net loss widened 38% to CHF 70.45 million

AC Immune reported FY 2025 contract revenue of CHF 3.57 million, down 87%, citing the prior-year recognition of a CHF 24.6 million ReTain-related milestone payment under its Janssen agreement. FY 2025 net loss after taxes was CHF 70.5 million and loss per share was CHF 0.70. FY 2025 R&D expense was CHF 56.44 million, down 10%, reflecting lower VacSYn manufacturing costs and completion of certain preclinical studies, partly offset by higher spend on the NLRP3 inhibitor and PET tracer programs. Cash resources were CHF 91.4 million at year-end, down 45%, and the company said this funds operations into Q3 2027. For FY 2026, AC Immune guided total cash expenditure of CHF 55-65 million, while CEO Andrea Pfeifer said Phase 2 interim data from ACI-7104 in early Parkinson’s disease suggest the active immunotherapy may slow disease progression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603130700OMX_____CNEWS_EN_GNW1001169941_en) on March 13, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619998621?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619998621","market":"fut","top_or_hot":-1,"title":"AC Immune FY2025 contract revenue fell 87% to CHF 3.57 million as net loss widened 38% to CHF 70.45 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AC Immune FY2025 contract revenue fell 87% to CHF 3.57 million as net loss widened 38% to CHF 70.45 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AC Immune reported FY 2025 contract revenue of CHF 3.57 million, down 87%, citing the prior-year recognition of a CHF 24.6 million ReTain-related milestone payment under its Janssen agreement. FY 2025 net loss after taxes was CHF 70.5 million and loss per share was CHF 0.70. FY 2025 R&amp;D expense was CHF 56.44 million, down 10%, reflecting lower VacSYn manufacturing costs and completion of certain preclinical studies, partly offset by higher spend on the NLRP3 inhibitor and PET tracer programs. Cash resources were CHF 91.4 million at year-end, down 45%, and the company said this funds operations into Q3 2027. For FY 2026, AC Immune guided total cash expenditure of CHF 55-65 million, while CEO Andrea Pfeifer said Phase 2 interim data from ACI-7104 in early Parkinson’s disease suggest the active immunotherapy may slow disease progression.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603130700OMX_____CNEWS_EN_GNW1001169941_en) on March 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AC Immune FY2025 contract revenue fell 87% to CHF 3.57 million as net loss widened 38% to CHF 70.45 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAC Immune FY2025 contract revenue fell 87% to CHF 3.57 million as net loss widened 38% to CHF 70.45 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-13 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AC Immune FY2025 contract revenue fell 87% to CHF 3.57 million as net loss widened 38% to CHF 70.45 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AC Immune reported FY 2025 contract revenue of CHF 3.57 million, down 87%, citing the prior-year recognition of a CHF 24.6 million ReTain-related milestone payment under its Janssen agreement. FY 2025 net loss after taxes was CHF 70.5 million and loss per share was CHF 0.70. FY 2025 R&amp;D expense was CHF 56.44 million, down 10%, reflecting lower VacSYn manufacturing costs and completion of certain preclinical studies, partly offset by higher spend on the NLRP3 inhibitor and PET tracer programs. Cash resources were CHF 91.4 million at year-end, down 45%, and the company said this funds operations into Q3 2027. For FY 2026, AC Immune guided total cash expenditure of CHF 55-65 million, while CEO Andrea Pfeifer said Phase 2 interim data from ACI-7104 in early Parkinson’s disease suggest the active immunotherapy may slow disease progression.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603130700OMX_____CNEWS_EN_GNW1001169941_en) on March 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014021.USD","symbol_name":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL5YB6Mc:1","article_id":"2619998621","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619998621","pubTimestamp":1773399658,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AC Immune reported FY 2025 contract revenue of CHF 3.57 million, down 87%, citing the prior-year recognition of a CHF 24.6 million ReTain-related milestone payment under its Janssen agreement. FY 2025 net loss after taxes was CHF 70.5 million and loss per share was CHF 0.70. FY 2025 R&D expense was CHF 56.44 million, down 10%, reflecting lower VacSYn manufacturing costs and completion of certain preclinical studies, partly offset by higher spend on the NLRP3 inhibitor and PET tracer programs. Cash resources were CHF 91.4 million at year-end, down 45%, and the company said this funds operations into Q3 2027. For FY 2026, AC Immune guided total cash expenditure of CHF 55-65 million, while CEO Andrea Pfeifer said Phase 2 interim data from ACI-7104 in early Parkinson’s disease suggest the active immunotherapy may slow disease progression.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4588":"碎股","BK4585":"ETF&股票定投概念","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","ACIU":"AC Immune SA","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"AC Immune 2025财年合同收入下降87%至357万瑞士法郎，净亏损扩大38%至7045万瑞士法郎","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ACIU":0.9},"content_text":"AC Immune FY2025 contract revenue fell 87% to CHF 3.57 million as net loss widened 38% to CHF 70.45 million\n    \n\n        AC Immune reported FY 2025 contract revenue of CHF 3.57 million, down 87%, citing the prior-year recognition of a CHF 24.6 million ReTain-related milestone payment under its Janssen agreement. FY 2025 net loss after taxes was CHF 70.5 million and loss per share was CHF 0.70. FY 2025 R&D expense was CHF 56.44 million, down 10%, reflecting lower VacSYn manufacturing costs and completion of certain preclinical studies, partly offset by higher spend on the NLRP3 inhibitor and PET tracer programs. Cash resources were CHF 91.4 million at year-end, down 45%, and the company said this funds operations into Q3 2027. For FY 2026, AC Immune guided total cash expenditure of CHF 55-65 million, while CEO Andrea Pfeifer said Phase 2 interim data from ACI-7104 in early Parkinson’s disease suggest the active immunotherapy may slow disease progression.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603130700OMX_____CNEWS_EN_GNW1001169941_en) on March 13, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619998621","isCrawlerRequest":true}